
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Inactivated EV71 Enterovirus Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Envacgen (Inactivated EV71 Enterovirus Vaccine) is a Vaccine drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Hand, Foot and Mouth Disease.
Product Name : Envacgen
Product Type : Vaccine
Upfront Cash : Inapplicable
September 17, 2025
Lead Product(s) : Inactivated EV71 Enterovirus Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : MVC-COV1901
Therapeutic Area : Undisclosed
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study to Evaluate Immunogenicity and Safety of MVC-COV1901 Vaccine Compared With AZD1222
Details : MVC-COV1901 is a Vaccine drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
June 22, 2022
Lead Product(s) : MVC-COV1901
Therapeutic Area : Undisclosed
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : BW-1019
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Recipient : BlueWillow Biologics
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : BW-1019, an intranasal COVID-19 booster, elicits mucosal immunity, stopping spread at the entry of the virus and, provided protection and boosted immune response when administered following an intramuscular vaccine series in preclinical studies.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
March 02, 2022
Lead Product(s) : BW-1019
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Recipient : BlueWillow Biologics
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : MVC-COV1901
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : MVC-COV1901 is a Vaccine drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
January 31, 2022
Lead Product(s) : MVC-COV1901
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : MVC-COV1901
Therapeutic Area : Undisclosed
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : MVC-COV1901 is a Vaccine drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
January 20, 2022
Lead Product(s) : MVC-COV1901
Therapeutic Area : Undisclosed
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : MVC-COV1901
Therapeutic Area : Undisclosed
Study Phase : Phase II
Sponsor : Coalition for Epidemic Preparedness Innovations
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : MVC-COV1901 is a Vaccine drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
January 19, 2022
Lead Product(s) : MVC-COV1901
Therapeutic Area : Undisclosed
Highest Development Status : Phase II
Sponsor : Coalition for Epidemic Preparedness Innovations
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Tozinameran,BNT162b2
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I/ Phase II
Recipient : Chang Gung Memorial Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable
The Immune Response of Heterologous Boost Third Dose of mRNA and Protein COVID-19 Vaccine
Details : Corminaty (BNT162b2) is a Vaccine drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of COVID-19.
Product Name : Corminaty
Product Type : Vaccine
Upfront Cash : Inapplicable
November 24, 2021
Lead Product(s) : Tozinameran,BNT162b2
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I/ Phase II
Recipient : Chang Gung Memorial Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : MVC-COV1901
Therapeutic Area : Undisclosed
Study Phase : Phase IV
Recipient : Taoyuan General Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : MVC-COV1901 is a Vaccine drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
October 27, 2021
Lead Product(s) : MVC-COV1901
Therapeutic Area : Undisclosed
Highest Development Status : Phase IV
Recipient : Taoyuan General Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : MVC-COV1901,Aluminium Hydroxide,CPG ODN 1018
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Phase II Data Of Medigen COVID-19 Vaccine, Reviewed And Published In The Lancet Respiratory Medicine
Details : The results from study served as basis for immunobriding that gives MVC-COV1901 vaccine's Emergency Use Authorization in Taiwan and can support the advancement in subsequent developments.MVC-COV1901 vaccine involves molecular modifications to S-2P pre-fu...
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
October 14, 2021
Lead Product(s) : MVC-COV1901,Aluminium Hydroxide,CPG ODN 1018
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : MVC-COV1901
Therapeutic Area : Undisclosed
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : MVC-COV1901 is a Vaccine drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
September 17, 2021
Lead Product(s) : MVC-COV1901
Therapeutic Area : Undisclosed
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
